Near Infrared Imaging, Inc
Wrentham, MA 02093, US
Medical Devices & Equipment
Near Infrared Imaging is recording revenue and earning profits with its first product, the Vein-Eye™. With funding, we will jump-start sales, triple our distributors, release new products and increase our revenues and profits significantly.
Near Infrared Imaging (NII) is on the cusp of causing a paradigm shift in medical imaging. NII’s patented technologies are revolutionary, life-saving, safe, non radiation, non-contact, non-invasive and affordable to the worldwide population.
Near Infrared Imaging (NII) incorporated in 2009 as an LLC, merged into a Delaware INC, is a “Corporation In Good Standing” with the Commonwealth of Massachusetts and has filed and paid all of its Federal and State taxes every year.
Near Infrared Imaging is owned in part by:
• The Regents of the University of California (UCLA)
• The City University of New York (CUNY)
• Lawrence Livermore National Laboratory (LLNL)
Our #1 competitor spent $23M to get to this same point that we are now. We accomplished this with $800,000. There are no VC or Angel investors. All of our investors are Mom and Pop investors who believe in the technology and the NII team. We only have 3M shares Authorized and 2M shares Outstanding. We will limit dilution and plan on an early exit strategy.
Near Infrared Imaging’s first product is the Vein-Eye™, a vein illumination camera that is priced significantly less than the leading selling devices. The Vein-Eye is already selling in more than 35 countries and generating profits and cash flow. We have over 45 distributors and are adding a distributor a week. This is all done with virtually no marketing, advertising, and a very limited sales force.
Investment funds will go directly to increasing sales and releasing new products already in development.
Products / Services
The Vein-Eye™ provides real-time video of sub-dermal veins located on various parts of the body, particularly the patient’s arm or hand. The video displays a “runway” image of the patient’s vein, necessary for IV placements.
One in three vein puncture attempts result in failure in adults, and one in two attempts result in failure in pediatrics. That translates to a 50% failure for first-time punctures in pediatrics.
The failure rate of vein punctures ranges from 10% to 40% with critically ill patients, where time is of the essence and vein punctures are challenging.
When a healthcare professional inserts a needle for an IV, it should be accomplished in a timely and safe manner. While vein illumination is important in every needle insertion, it is paramount if the patient is obese, very young, aged or has dark skin.
The Vein-Eye™ is an FDA Class1, 510K exempt medical device and has the CE Marking.
President Executive Officer
The management, employees and consultants are all sincere, hard-working, and very capable. There are no egos here. We realize that we are onto something revolutionary, as many of our technologies will cause a shift in medical imaging. It is our responsibility to our investors, ourselves and the worldwide community to be successful – and soon.
Dr. Madan is a Neuroradiologist at Tufts University Medical Center, Boston, MA.
Dr. Ryan Abbott has an MD and a JD and teaches at UCLA’s Medical School.
Mikhail Fridberg has MSEE and great experience in many aspects of product design, including writing algorithms..
Ross Goldman has an MBA and is our financial expert, preparing pro-formas, income statements and tax documents.
Dr. Hossam El Enein is an MD in Egypt, assisting NII in developing distributors in the Middle East.
Dr. Elseidy is an MD assisting us in the MENA area.